Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Life Sciences Holdings Inc.

www.advancedlifesciences.com

Latest From Advanced Life Sciences Holdings Inc.

An Emerging Approval Trend At FDA: More First-Time Sponsors

There is a surprising trend in the list of FDA approvals in 2011: an increase in the number of small biopharma companies opting to forgo Big Pharma partnerships and submit new product applications on their own. Here’s how these “emerging sponsors” are changing the way FDA does business—for big and small companies alike.

BioPharmaceutical Drug Approval Standards

Covington's Lam appointed to Cytochroma board

Cytochroma, a speciality pharmaceutical company developing products to treat and prevent the consequences of vitamin D insufficiency and secondary hyperparathyroidism, has appointed Lily Lam to its board of directors. She will replace Dr Cynthia Lavoie of VG Partners and VenGrowth Advanced Life Sciences Fund, which has been acquired by the Covington Fund, a new investor in Cytochroma. Ms Lam is vice-president of investments at Covington Capital.

Metabolic Disorders

Advanced Life enters suspended animation, and considers corporate or asset sale

Advanced Life Sciences, a novel antibiotics firm based in Chicago, Illinois which has suffered setbacks in bringing to market its lead investigational candidate Restanza (cefthromycin), has suspended operations and terminated its staff due to a severe cash shortage. "We presently do not have sufficient cash to fund our operations and have curtailed substantially all activities", company chairman and CEO Dr Michael Flavin said in a statement.

Infectious Diseases

Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances

FDA's effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms. This article first appeared in the May 2011 issue of The RPM Report.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Advanced Life Sciences Holdings Inc.
  • Senior Management
  • Michael T Falvin, PhD, Chmn. & CEO
    John L Flavin, Pres. & CFO
    Suseelan Pookote, PhD, EVP, Corp. Dev.
    Ze-Qi Xu, PhD, EVP, CSO
  • Contact Info
  • Advanced Life Sciences Holdings Inc.
    Phone: (630) 739-6744
    1440 Davey Rd.
    Woodbridge, IL 60517
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register